What happened with ALVO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Alvotech makes medicines designed to match existing biological drugs without clinically meaningful differences in safety or effectiveness. These are called biosimilars. Its main commercial products are AVT02, a biosimilar to Humira sold as SIMLANDI in the United States and Canada, and AVT04, a biosimilar to Stelara sold as SELARSDI in the United States.
Alvotech has no direct sales or distribution network. Partners such as Teva, STADA and Advanz Pharma bring its medicines to market under territorial licenses. They pay Alvotech upfront and milestone payments as development, approvals and launches progress, then pay for product supply under arrangements linked to their sales or agreed minimum prices. License and milestone payments are the larger revenue stream, alongside substantial product-supply revenue. Most revenue comes from a small group of customers, so Alvotech depends heavily on its partners’ development commitments and selling efforts.
Alvotech manufactures the biological drug substance for all its programs at its Reykjavik facility in Iceland. Revenue depends on reliable production, regulatory approvals and partners securing insurance coverage and reimbursement. FDA findings at that facility delayed U.S. approvals for AVT03, AVT05 and AVT06. Market entry also depends on clearing relevant patents and regulatory exclusivity, rather than simply finishing development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Alvotech’s results also hinge on biosimilar launches, milestone payments and sales through European commercialization partners Advanz Pharma and STADA, neither of which appears in this list.
Teva buys Alvotech’s biosimilars and sells them exclusively in the United States, making its launches and sales a direct source of Alvotech’s supply revenue and milestone payments; it also competes with Alvotech’s AVT23 program. Alvotech develops and supplies the medicines and, subject to limitations, receives 40% of Teva’s net sales value for that supply.
Amgen competes with Alvotech’s adalimumab and ustekinumab biosimilars and sells Prolia and XGEVA, the original denosumab medicines that Alvotech’s AVT03 seeks to replace. Watch Amgen’s patent suit over AVT03: it is seeking an injunction against the proposed competing medicine.
Dr. Reddy’s sells Alvotech’s denosumab biosimilar under a partnership covering the United States and Europe, giving Alvotech a route to market while it develops and supplies the medicine. Watch the patent litigation over AVT03: a ruling for Amgen could affect the partners’ U.S. market access.
AbbVie’s Humira competes with Alvotech’s adalimumab biosimilar AVT02 for immunology prescriptions and reimbursement. Watch Humira’s prices and sales volumes: AbbVie identifies biosimilar substitution and price competition as pressures on its medicine revenue.
Johnson & Johnson’s Janssen-originated Stelara competes with Alvotech’s ustekinumab biosimilar for immunology treatment sales.
Regeneron’s EYLEA competes with Alvotech’s AVT06, and patent settlements set when Alvotech and its partners can start selling their alternative. The U.S. settlement permits entry in the fourth quarter of 2026, or earlier in certain circumstances—an important date to watch for AVT06 sales.
Amneal Pharmaceuticals, Inc. is an expected competitor to Alvotech’s denosumab program AVT03 and already sells biosimilars through its Affordable Medicines business. Watch that business’s biosimilar launches for competition facing AVT03.
Pfizer’s approved adalimumab biosimilar competes with Alvotech’s AVT02 in the United States and European Economic Area. Pfizer sells biopharmaceutical medicines and negotiates pricing and contracts with payors, making its pricing arrangements worth watching for AVT02’s competitive position.
Fed Interest Rate Decision
Alvotech’s Fed-rate exposure runs through its $1.03 billion first-lien loan: the decision can affect SOFR, the benchmark rate used to set its interest payments, and thus the cash left for developing and supplying biosimilars through partners.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets a higher rate than expected, rising SOFR would increase interest on the first-lien loan, leaving Alvotech less cash for biosimilar development and manufacturing for its partners.
If it comes in below expectations
If the Fed sets a lower rate than expected, falling SOFR would reduce interest on the first-lien loan, leaving Alvotech more cash for biosimilar development and manufacturing for its partners.
Alvotech earningsThis company
Alvotech’s report will show whether partner sales of its biosimilars are adding product revenue alongside licensing and development income.
Read product revenue alongside license and other revenue, and distinguish ongoing development services from payments triggered by launches or sales milestones. Growing product revenue with continuing licensing income would show partners are turning approved medicines into sales; if growth rests mainly on one-off milestones or product revenue stalls, the business and cash generation remain more dependent on a few products and partners.
